LOGIN  |  REGISTER
Viking Therapeutics

McKesson Raises Quarterly Dividend by 15% to $0.62 Per Share

July 24, 2023 | Last Trade: US$866.03 16.57 1.95

IRVING, Texas / Jul 24, 2023 / Business Wire / The Board of Directors of McKesson Corporation (NYSE:MCK) declared on July 21, 2023 a regular dividend of $0.62 per share of common stock, a 15% increase from $0.54 per share in the prior quarter. The dividend will be payable on October 2, 2023, to stockholders of record on September 1, 2023.

“The dividend increase reflects confidence in our strategy and ability to generate sustained strong cash flows,” said Brian Tyler, chief executive officer. “We continue to remain disciplined in our approach to capital deployment and focused on driving sustainable growth while creating value for our shareholders.”

McKesson has increased its dividend for seven consecutive years.

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.

Viking Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page